2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

Journal of Hypertension, Journal Year: 2023, Volume and Issue: 41(12), P. 1874 - 2071

Published: June 24, 2023

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici (Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luís Bronze (Portugal), John Chalmers (Australia), Tine De Backer (Belgium), Alejandro de la Sierra (Spain), Kyriakos Dimitriadis Dorota Drozdz (Poland), Béatrice Duly-Bouhanick (France), Brent M. Egan (USA), Serap Erdine Claudio Ferri (Italy), Slavomira Filipova (Slovak Republic), Anthony Heagerty (UK), Michael Hecht Olsen (Denmark), Dagmara Hering Sang Hyun Ihm (South Korea), Uday Jadhav (India), Manolis Kallistratos Kazuomi Kario (Japan), Vasilios Kotsis Adi Leiba (Israel), Patricio López-Jaramillo (Colombia), Hans-Peter Marti (Norway), Terry McCormack Paolo Mulatero Dike B. Ojji (Nigeria), Sungha Park Priit Pauklin (Estonia), Sabine Perl (Austria), Arman Postadzhian (Bulgaria), Aleksander Prejbisz Venkata Ram Ramiro Sanchez (Argentina), Markus Schlaich Alta Schutte Cristina Sekib Sokolovic (Bosnia and Herzegovina), Jonas Spaak (Sweden), Dimitrios Terentes-Printzios Bruno Trimarco Thomas Unger (The Netherlands), Bert-Jan van den Born Anna Vachulova Agostino Virdis Jiguang Wang (China), Ulrich Wenzel (Germany), Paul Whelton Jiri Widimsky (Czech Jacek Wolf Grégoire Wuerzner (Switzerland), Eugene Yang Yuqing Zhang (China).

Language: Английский

---

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Circulation, Journal Year: 2023, Volume and Issue: 149(1)

Published: Nov. 30, 2023

The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation" provides recommendations to guide clinicians in treatment patients with atrial fibrillation.

Language: Английский

---

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

Circulation, Journal Year: 2024, Volume and Issue: 149(8)

Published: Jan. 24, 2024

BACKGROUND: The American Heart Association (AHA), in conjunction with the National Institutes of Health, annually reports most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, nutrition, sleep, obesity) factors (cholesterol, blood pressure, glucose control, metabolic syndrome) that contribute health. AHA Disease Stroke Statistical Update presents latest data on a range major clinical circulatory disease conditions (including brain health, complications pregnancy, kidney congenital rhythm disorders, sudden cardiac arrest, subclinical atherosclerosis, coronary cardiomyopathy, failure, valvular venous thromboembolism, peripheral artery disease) associated outcomes quality care, procedures, economic costs). METHODS: AHA, through its Epidemiology Prevention Statistics Committee, continuously monitors evaluates sources stroke United States globally provide current information available annual review published literature year before writing. 2024 is product full year’s worth effort 2023 by dedicated volunteer clinicians scientists, committed government professionals, staff members. strives further understand help heal problems inflicted structural racism, public crisis can significantly damage mental perpetuate disparities access education, income, housing, several other vital healthy lives. This edition includes additional global data, as well monitoring benefits population, an enhanced focus equity across key domains. RESULTS: Each chapters focuses different topic statistics. CONCLUSIONS: represents critical resource for lay public, policymakers, media clinicians, care administrators, researchers, advocates, others seeking best these conditions.

Language: Английский

---

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Circulation, Journal Year: 2022, Volume and Issue: 145(18)

Published: April 1, 2022

The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" replaces "2013 ACCF/AHA and "2017 ACC/AHA/HFSA Focused Update 2013 Failure." 2022 guideline is intended to provide patient-centric recommendations clinicians prevent, diagnose, manage patients with heart failure.A comprehensive literature search was conducted from May 2020 December 2020, encompassing studies, reviews, other evidence on human subjects that were published in English MEDLINE (PubMed), EMBASE, Cochrane Collaboration, Agency Healthcare Research Quality, relevant databases. Additional clinical trials research through September 2021, also considered. This harmonized American Association/American College Cardiology guidelines 2021. Structure: failure remains a leading cause morbidity mortality globally. provides based contemporary treatment these patients. present an evidence-based approach managing failure, intent improve quality care align patients' interests. Many earlier have been updated new evidence, created when supported by data. Value statements are provided certain treatments high-quality economic analyses.

Language: Английский

---

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

Circulation, Journal Year: 2023, Volume and Issue: 148(9)

Published: July 20, 2023

AIM: The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease” provides an update to and consolidates new evidence since “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Diagnosis Stable Ischemic Heart corresponding “2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update Disease.” METHODS: A comprehensive literature search was conducted from September 2021 May 2022. Clinical studies, systematic reviews meta-analyses, other on human participants were identified that published in English MEDLINE (through PubMed), EMBASE, Cochrane Library, Agency Healthcare Research Quality, selected databases relevant this guideline. STRUCTURE: This guideline evidenced-based patient-centered approach management patients with chronic coronary disease, considering social determinants health incorporating principles shared decision-making team-based care. Relevant topics include general approaches treatment decisions, guideline-directed therapy reduce symptoms future cardiovascular events, pertaining revascularization recommendations special populations, patient follow-up monitoring, gaps, areas need research. Where applicable, based availability cost-effectiveness data, cost–value are also provided clinicians. Many previously guidelines have been updated evidence, created when supported by data.

Language: Английский

---

Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association

Circulation, Journal Year: 2023, Volume and Issue: 148(20), P. 1606 - 1635

Published: Oct. 9, 2023

Cardiovascular-kidney-metabolic health reflects the interplay among metabolic risk factors, chronic kidney disease, and cardiovascular system has profound impacts on morbidity mortality. There are multisystem consequences of poor cardiovascular-kidney-metabolic health, with most significant clinical impact being high associated incidence disease events is a prevalence in population, disproportionate burden seen those adverse social determinants health. However, there also growing number therapeutic options that favorably affect function, or both have cardioprotective effects. To improve related outcomes critical need for (1) more clarity definition syndrome; (2) an approach to staging promotes prevention across life course; (3) prediction algorithms include exposures relevant health; (4) strategies management relation reflect harmonization major subspecialty guidelines emerging scientific evidence. It incorporate considerations into care models syndrome reduce fragmentation by facilitating approaches patient-centered interdisciplinary care. This presidential advisory provides guidance definition, staging, paradigms, holistic patients details multicomponent vision effectively equitably enhancing population.

Language: Английский

---

Acetazolamide in Acute Decompensated Heart Failure with Volume Overload

New England Journal of Medicine, Journal Year: 2022, Volume and Issue: 387(13), P. 1185 - 1195

Published: Aug. 27, 2022

Whether acetazolamide, a carbonic anhydrase inhibitor that reduces proximal tubular sodium reabsorption, can improve the efficiency of loop diuretics, potentially leading to more and faster decongestion in patients with acute decompensated heart failure volume overload, is unclear.

Language: Английский

---

Heart Failure With Preserved Ejection Fraction

JAMA, Journal Year: 2023, Volume and Issue: 329(10), P. 827 - 827

Published: March 14, 2023

Heart failure with preserved ejection fraction (HFpEF), defined as HF an EF of 50% or higher at diagnosis, affects approximately 3 million people in the US and up to 32 worldwide. Patients HFpEF are hospitalized 1.4 times per year have annual mortality rate 15%.Risk factors for include older age, hypertension, diabetes, dyslipidemia, obesity. Approximately 65% patients present dyspnea physical examination, chest radiographic, echocardiographic, invasive hemodynamic evidence overt congestion (volume overload) rest. 35% "unexplained" on exertion, meaning they do not clear physical, echocardiographic signs HF. These elevated atrial pressures exercise measured stress testing estimated Doppler echocardiography testing. In unselected presenting unexplained dyspnea, H2FPEF score incorporating clinical (age, obesity, fibrillation status) resting (estimated pulmonary artery systolic pressure left pressure) variables can assist diagnosis (H2FPEF range, 0-9; >5 indicates more than 95% probability HFpEF). Specific causes syndrome normal other should be identified treated, such valvular, infiltrative, pericardial disease. First-line pharmacologic therapy consists sodium-glucose cotransporter type 2 inhibitors, dapagliflozin empagliflozin, which reduced hospitalization cardiovascular death by 20% compared placebo randomized trials. Compared usual care, training diet-induced weight loss produced clinically meaningful increases functional capacity quality life Diuretics (typically loop diuretics, furosemide torsemide) prescribed improve symptoms. Education self-care (eg, adherence medications dietary restrictions, monitoring symptoms vital signs) help avoid decompensation.Approximately HFpEF. exercise, self-care, diuretics needed maintain euvolemia, obesity

Language: Английский

---

Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial

The Lancet, Journal Year: 2022, Volume and Issue: 400(10369), P. 2199 - 2209

Published: Nov. 5, 2022

Language: Английский

---

A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association

Circulation, Journal Year: 2023, Volume and Issue: 148(20), P. 1636 - 1664

Published: Oct. 9, 2023

A growing appreciation of the pathophysiological interrelatedness metabolic risk factors such as obesity and diabetes, chronic kidney disease, cardiovascular disease has led to conceptualization cardiovascular-kidney-metabolic syndrome. The confluence within syndrome is strongly linked for adverse outcomes. In addition, there are unique management considerations individuals with established coexisting factors, or both. An extensive body literature supports our scientific understanding of, approach to, prevention However, critical gaps in knowledge related terms mechanisms development, heterogeneity clinical phenotypes, interplay between social determinants health biological accurate assessments incidence context competing risks. There also key limitations data supporting care syndrome, particularly early-life prevention, screening interdisciplinary models, optimal strategies lifestyle modification weight loss, targeting emerging cardioprotective kidney-protective therapies, patients both impact systematically assessing addressing health. This statement uses a crosswalk major guidelines, addition review literature, summarize evidence fundamental science, screening,

Language: Английский

---